These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 25957525)

  • 1. The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease.
    Stadler K; Goldberg IJ; Susztak K
    Curr Diab Rep; 2015 Jul; 15(7):40. PubMed ID: 25957525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes.
    Proctor G; Jiang T; Iwahashi M; Wang Z; Li J; Levi M
    Diabetes; 2006 Sep; 55(9):2502-9. PubMed ID: 16936198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propionate Promotes Fatty Acid Oxidation through the Up-Regulation of Peroxisome Proliferator-Activated Receptor α in Intestinal Epithelial Cells.
    Higashimura Y; Naito Y; Takagi T; Uchiyama K; Mizushima K; Yoshikawa T
    J Nutr Sci Vitaminol (Tokyo); 2015; 61(6):511-5. PubMed ID: 26875495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
    Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
    Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis.
    Jao TM; Nangaku M; Wu CH; Sugahara M; Saito H; Maekawa H; Ishimoto Y; Aoe M; Inoue T; Tanaka T; Staels B; Mori K; Inagi R
    Kidney Int; 2019 Mar; 95(3):577-589. PubMed ID: 30639234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
    Guan Y
    Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of Lkb1 in Renal Tubular Epithelial Cells Leads to CKD by Altering Metabolism.
    Han SH; Malaga-Dieguez L; Chinga F; Kang HM; Tao J; Reidy K; Susztak K
    J Am Soc Nephrol; 2016 Feb; 27(2):439-53. PubMed ID: 26054542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
    Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
    Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle.
    Al-Khalili L; Bouzakri K; Glund S; Lönnqvist F; Koistinen HA; Krook A
    Mol Endocrinol; 2006 Dec; 20(12):3364-75. PubMed ID: 16945991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome-generated succinate induces lipid accumulation and oxidative stress in the kidneys of diabetic mice.
    Wang Y; Zhang X; Yao H; Chen X; Shang L; Li P; Cui X; Zeng J
    J Biol Chem; 2022 Mar; 298(3):101660. PubMed ID: 35124006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective effect of myricetin restrains dyslipidemia and renal mesangial cell proliferation by the suppression of sterol regulatory element binding proteins in an experimental model of diabetic nephropathy.
    Kandasamy N; Ashokkumar N
    Eur J Pharmacol; 2014 Nov; 743():53-62. PubMed ID: 25240712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
    Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
    Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1.
    Singh KK; Shukla PC; Yanagawa B; Quan A; Lovren F; Pan Y; Wagg CS; Teoh H; Lopaschuk GD; Verma S
    J Thorac Cardiovasc Surg; 2013 Sep; 146(3):702-9. PubMed ID: 23317938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
    Cheng L; Ge M; Lan Z; Ma Z; Chi W; Kuang W; Sun K; Zhao X; Liu Y; Feng Y; Huang Y; Luo M; Li L; Zhang B; Hu X; Xu L; Liu X; Huo Y; Deng H; Yang J; Xi Q; Zhang Y; Siegenthaler JA; Chen L
    Arch Toxicol; 2018 Jan; 92(1):469-485. PubMed ID: 28871336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
    Purushothaman S; Sathik MM; Nair RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):254-62. PubMed ID: 21654328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisomes in cardiomyocytes and the peroxisome / peroxisome proliferator-activated receptor-loop.
    Colasante C; Chen J; Ahlemeyer B; Baumgart-Vogt E
    Thromb Haemost; 2015 Mar; 113(3):452-63. PubMed ID: 25608554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice.
    Lu Y; Boekschoten MV; Wopereis S; Müller M; Kersten S
    Physiol Genomics; 2011 Dec; 43(23):1307-18. PubMed ID: 21954454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The key role of altered tubule cell lipid metabolism in kidney disease development.
    Lee LE; Doke T; Mukhi D; Susztak K
    Kidney Int; 2024 Jul; 106(1):24-34. PubMed ID: 38614389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.